In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Stryker’s MAKO Purchase Bring Disruption To The Ortho Industry?

Executive Summary

Stryker’s adoption of MAKO’s RIO (Robotic-arm Interactive Orthopedic) system could give the global medical supplier a competitive edge over other orthopedic implant makers if the company can win converts to robotic surgery by leveraging its own experience in selling capital equipment.

Advertisement

Related Content

Medtech 2013: Device Companies Go Where The Growth Is
Device/Diagnostics Quarterly Deal Statistics, Q3 2013
Robot Wars Brewing In Orthopedics
At AAOS Knee Implant Makers Pitch Better Fit, Precision
Large Joint Replacement Market: Set For A Rebound?
Stryker Enters China Race With Trauson Bid
OrthoSensor: Will Sensor-Enabled Data Transform Orthopedics?
Can ConforMIS Recharge Resurfacing with Custom Implants
MAKO Surgical: Navigating Robotics in Orthopedics
Stanmore: Creating a Specialty Orthopedics Company

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004112

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel